Validation of Questionnaire and Assessment of Patient Satisfaction for Budesonide/Formoterol Fix Combination Dry Powder Inhalers (DPI) in Chronic Obstructive Pulmonary Disease (COPD)

AstraZeneca

Status: Completed

Conditions: Chronic Obstructive Pulmonary Disease (COPD)

Study type: Observational

Funder types: Industry

Identifiers

NCT01646424

NIS-RTR-XXX-2012/1

Details and patient eligibility

About

The aim of this study is to describe patient preferences on budesonide/formoterol fix dose combination for the treatment of their COPD, and to find those factors more strongly associated to a better attitude to medication.

Full description

Validation of questionnaire and assessment of patient satisfaction for budesonide/formoterol fix combination DPI in COPD

Enrollment: 446 patients

Sex: All

Ages: 40+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Provision of subject informed consent and to be an outpatient
• Clinical diagnosis of COPD according to ICD-10 classification, females and males, aged ≥ 40 years
• To be prescribed a fixed dose combination of inhaled budesonide/formoterol fix combination at least 3 months before the study start

Exclusion criteria

• Pregnancy for women
• Use of inhaled medication via a metered dose inhaler (pMDI)
• Currently participating in randomized clinical trials and being included in this study once